{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:22:40Z","timestamp":1761578560614,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.ecl.2011.02.001","type":"journal-article","created":{"date-parts":[[2011,5,12]],"date-time":"2011-05-12T12:08:41Z","timestamp":1305202121000},"page":"279-294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Screening for Adrenal-Endocrine Hypertension: Overview of Accuracy and Cost-effectiveness"],"prefix":"10.1016","volume":"40","author":[{"given":"Gary L.","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2011.02.001_bib1","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2010.650","article-title":"US trends in prevalence, awareness, treatment, and control of hypertension, 1988\u20132008","volume":"303","author":"Egan","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2011.02.001_bib2","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jama.1996.03530440051036","article-title":"Blood pressure as a cardiovascular risk factor","volume":"275","author":"Kannel","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2011.02.001_bib3","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1161\/hs0302.103657","article-title":"Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review","volume":"33","author":"Gorelick","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.ecl.2011.02.001_bib4","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1161\/01.HYP.0000069699.92349.8C","article-title":"Blood pressure predicts risk of developing end-stage renal disease in men and women","volume":"41","author":"Tozawa","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.02.001_bib5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/jhh.2008.80","article-title":"Cognitive function and hypertension","volume":"23","author":"Birns","year":"2009","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.ecl.2011.02.001_bib6","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(01)06411-X","article-title":"Cardiovascular protection and blood pressure reduction: a meta-analysis","volume":"358","author":"Staessen","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2011.02.001_bib7","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ecl.2011.02.001_bib8","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/archinte.1987.00370070103015","article-title":"Secondary hypertension in a blood pressure clinic","volume":"147","author":"Sinclair","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ecl.2011.02.001_bib9","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A\u00a0prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2011.02.001_bib10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1525-1497.1997.07107.x","article-title":"Assessing the effectiveness of health interventions for cost-effectiveness analysis","volume":"12","author":"Mandelblatt","year":"1997","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.ecl.2011.02.001_bib11","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the Panel on Cost-effectiveness in Health and Medicine","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2011.02.001_bib12","series-title":"Clinical epidemiology, the essentials","first-page":"42","article-title":"Diagnosis","author":"Fletcher","year":"1988"},{"key":"10.1016\/j.ecl.2011.02.001_bib13","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1097\/HJH.0b013e3281268532","article-title":"Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension","volume":"25","author":"Holaj","year":"2007","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ecl.2011.02.001_bib14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1161\/HYPERTENSIONAHA.108.117044","article-title":"Effects of aldosterone on the heart: beyond systemic hemodynamics?","volume":"52","author":"Diez","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.02.001_bib15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1210\/jc.2008-1851","article-title":"Risk factors associated with low glomerular filtration rate in primary aldosteronism","volume":"94","author":"Reincke","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2011.02.001_bib16","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2011.02.001_bib17","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline","volume":"93","author":"Funder","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2011.02.001_bib18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1161\/HYPERTENSIONAHA.106.086124","article-title":"Is there an unrecognized epidemic of primary aldosteronism? (Con)","volume":"50","author":"Kaplan","year":"2007","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ecl.2011.02.001_bib19","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1373\/clinchem.2004.041780","article-title":"Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity","volume":"51","author":"Schwartz","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.ecl.2011.02.001_bib20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","article-title":"Primary aldosteronism and hypertensive disease","volume":"42","author":"Mosso","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.02.001_bib21","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"High prevalence of primary aldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.02.001_bib22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0272-6386(01)80117-7","article-title":"Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio","volume":"37","author":"Gallay","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ecl.2011.02.001_bib23","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","article-title":"Low-renin status in therapy-resistant hypertension: a clue to efficient treatment","volume":"22","author":"Eide","year":"2004","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ecl.2011.02.001_bib24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.jhh.1001554","article-title":"Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the central Europe region","volume":"17","author":"Strauch","year":"2003","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.ecl.2011.02.001_bib25","series-title":"Clinical hypertension","first-page":"459","article-title":"Primary aldosteronism","author":"Kaplan","year":"2002"},{"key":"10.1016\/j.ecl.2011.02.001_bib26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.7326\/0003-4819-135-4-200108210-00010","article-title":"Primary aldosteronism: factors associated with normalization of blood pressure after surgery","volume":"135","author":"Sawka","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ecl.2011.02.001_bib27","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0889-8529(02)00013-0","article-title":"Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature","volume":"31","author":"Montori","year":"2002","journal-title":"Endocinol Metab Clin North Am"},{"key":"10.1016\/j.ecl.2011.02.001_bib28","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1210\/jc.2002-021476","article-title":"Variability in the renin\/aldosterone profile under random and standardized sampling conditions in primary aldosteronism","volume":"88","author":"Tanabe","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2011.02.001_bib29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00004872-200402000-00006","article-title":"The challenge of more robust and reproducible methodology in screening for primary aldosteronism","volume":"22","author":"Gordon","year":"2004","journal-title":"J\u00a0Hypertens"},{"issue":"11","key":"10.1016\/j.ecl.2011.02.001_bib30","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1093\/clinchem\/48.11.1919","article-title":"Screening for primary aldosteronism: implications of an increased plasma aldosterone\/renin ratio","volume":"48","author":"Schwartz","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.ecl.2011.02.001_bib31","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0025-6196(11)62105-8","article-title":"Validity of the aldosterone-renin ratio to screen for primary aldosteronism","volume":"76","author":"Montori","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ecl.2011.02.001_bib32","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02775.x","article-title":"Primary aldosteronism: renaissance of a syndrome","volume":"66","author":"Young","year":"2007","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ecl.2011.02.001_bib33","first-page":"55","article-title":"Hypertension and pheochromocytoma testing: the association with anxiety orders","volume":"3","author":"Fogarty","year":"1994","journal-title":"Arch Fam Med"},{"key":"10.1016\/j.ecl.2011.02.001_bib34","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1210\/jc.2003-031127","article-title":"The economic implications of three biochemical screening algorithms for pheochromocytoma","volume":"89","author":"Sawka","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2011.02.001_bib35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.7326\/0003-4819-134-4-200102200-00016","article-title":"NIH Conference. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma","volume":"134","author":"Pacak","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ecl.2011.02.001_bib36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/pr.56.3.1","article-title":"Catecholamine metabolism: a contemporary view with implications for physiology and medicine","volume":"56","author":"Eisenhofer","year":"2004","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ecl.2011.02.001_bib37","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jama.287.11.1427","article-title":"Biochemical diagnosis of pheochromocytoma. Which test is best?","volume":"287","author":"Lenders","year":"2002","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ecl.2011.02.001_bib38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/00313020802579284","article-title":"Plasma free metanephrines are superior to urine and plasma catecholamine metabolites for the investigation of pheochromocytoma","volume":"41","author":"Hickman","year":"2009","journal-title":"Pathology"},{"issue":"2","key":"10.1016\/j.ecl.2011.02.001_bib39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ncpendmet0396","article-title":"Pheochromocytoma: recommendations for clinical practice from the First International Symposium","volume":"3","author":"Pacak","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.ecl.2011.02.001_bib40","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.cca.2010.01.012","article-title":"Performance of plasma free metanephrines measured by liquid chromatography-tandem mass spectrometry in the diagnosis of pheochromocytoma","volume":"411","author":"Peaston","year":"2010","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ecl.2011.02.001_bib41","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1523-1755.2005.67123.x","article-title":"Plasma metanephrines in renal failure","volume":"67","author":"Eisenhofer","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ecl.2011.02.001_bib42","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2265.2007.02805.x","article-title":"The diagnostic accuracy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma","volume":"66","author":"Perry","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ecl.2011.02.001_bib43","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1530\/EJE-09-0996","article-title":"Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma","volume":"162","author":"Grouzmann","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ecl.2011.02.001_bib44","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1210\/jc.2002-030005","article-title":"Biochemical diagnosis of pheochromocytoma: how to distinguish true-from false-positive test results","volume":"88","author":"Eisenhofer","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2011.02.001_bib45","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1210\/jc.2009-0303","article-title":"Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors","volume":"94","author":"de Jong","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2011.02.001_bib46","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/jc.2007-1354","article-title":"Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma","volume":"93","author":"Algeciras-Schimnich","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852911000326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852911000326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:33:41Z","timestamp":1760175221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852911000326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0889852911000326"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2011.02.001","relation":{},"ISSN":["0889-8529"],"issn-type":[{"type":"print","value":"0889-8529"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening for Adrenal-Endocrine Hypertension: Overview of Accuracy and Cost-effectiveness","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2011.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}